This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Bristol-Myers Squibb Company
Drug Names(s): delcasertib
Description: KAI-9803 is a selective inhibitor of the delta variant (isoenzyme) of Protein Kinase C, a modulator of both the apoptosis cascade and mitochondrial damage leading to cellular necrosis in reperfusion injury after a heart attack. It disrupts binding of activated deltaPKC with its RACK (receptor for activated C-kinase).
KAI and Daiichi Sankyo
In January 2006, KAI Pharmaceuticals and Daiichi Sankyo announced that Sankyo Company, Limited, a wholly owned subsidiary of Daiichi Sankyo, and KAI Pharmaceuticals entered an agreement for the global development and commercialization of KAI-9803. Under the terms of the partnership, Sankyo will make an initial payment to KAI of $20 million. In addition, KAI could receive potential development and commercialization milestones of up to $300 million for two initial indications for KAI-9803, as well as milestone payments for future delta PKC inhibitors. Sankyo will fund all future development, and will have global development and commercialization rights and pay KAI a double-digit royalty on sales.
KAI will have the option to perform certain clinical studies. In North America, KAI will have the right to co-promote products in the acute care/hospital setting. KAI may receive $20 million from Sankyo in research support over five years to identify new...See full deal structure in Biomedtracker
Partners: Amgen, Inc.
Scrip KAI Pharmaceuticals Inc.
Pink Sheet BMS Licenses Kai Heart Drug For $227 Million
Pink Sheet Bristol Recharges Kai Heart Attack Candidate
Additional information available to subscribers only: